Search clinical trials for: Fluticasone Furoate (200mcg unit strength)

Total 187 results

GlaxoSmithKline

Completed

Study to Look at and Compare How Inhaled and Intravenous Fluticasone Furoate is Processed by the Body in Healthy Caucasian, Japanese, Korean and Chinese Subjects

Asthma

Australia
GlaxoSmithKline

Completed

Study FFR116365, an Open-label Study of GW685698X in Paediatric Subjects With Perennial Allergic Rhinitis

Rhinitis

Japan
Manhattan Eye, Ear & Throat Hospital
Alcon Research

Terminated

Treatment of Rubeosis Iridis With Open-Label Anecortave Acetate Sterile Suspension ( 15 mg.).

Central Retinal Vein Occlusion | Severe Diabetic Retinopathy | Chronic Inflammation | Infectious Diseases

United States
GlaxoSmithKline

Completed

Study In Adults And Adolescents With Seasonal Allergic Rhinitis

Rhinitis, Allergic, Seasonal | Seasonal Allergic Rhinitis | Hayfever

United States
GlaxoSmithKline

Completed

Study FFR116364, a Placebo-controlled Study of GW685698X in Paediatric Subjects With Perennial Allergic Rhinitis

Rhinitis, Allergic, Perennial

Japan
University of Chicago
GlaxoSmithKline

Completed

Mechanism of Action of Fluticasone Furoate in Childhood Obstructive Sleep Apnea Syndrome

Childhood Obstructive Sleep Apnea Syndrome (OSAS)

United States
GlaxoSmithKline

Completed

Study Evaluating the Effect of Fluticasone Furoate/ Vilanterol (FF/VI) Inhalation Powder Compared With Vilanterol (VI) Inhalation Powder on Bone Mineral Density (BMD) in Subjects With Chronic Obstructive Pulmonary Disease (COPD).

Pulmonary Disease, Chronic Obstructive

United States, Germany, Spain, Netherlands, Canada
University of Chicago
GlaxoSmithKline

Completed

Effect of Veramyst on the Nasal and Ocular Symptoms of the Early Reaction to Nasal Challenge With Allergen

Allergic Rhinitis

United States
University of Chicago
GlaxoSmithKline

Completed

Intranasal Steroids and the Nasal Ocular Response

Seasonal Allergic Rhinitis

United States
Arthur F Gelb MD

Completed

Evaluation Inhaled Corticosteroids on Exhaled Nitric Oxide Gas Exchange

COPD

United States
University of Iowa

No longer available

Treatment of Patients With Age-Related Macular Degeneration With Anecortave Acetate

Macular Degeneration

United States
GlaxoSmithKline

Completed

Study Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) Compared With Vilanterol Inhalation Powder (VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Germany, Japan, Poland, Romania, Russian Federation, Ukraine, Taiwan, Bulgaria, South Africa, Korea, Republic of
Johns Hopkins University
GlaxoSmithKline

Terminated

Compare the Effects of Fluticasone Furoate Nasal Spray vs Placebo in Patients With Nasal Polypoid Disease

Patients With Nasal Polyps
GlaxoSmithKline

Completed

Study to Determine the Pharmacokinetics of GSK961081 and Fluticasone Furoate When Administered Alone or in Combination

Pulmonary Disease, Chronic Obstructive

Australia
GlaxoSmithKline

Completed

To Investigate the Effects of Altering the Time of Day of Dosing (Morning or Evening) With Fluticasone Furoate 100 Micrograms Once Daily Administered Via a Dry Powder Inhaler in Subjects With Asthma

Asthma

Australia
GlaxoSmithKline

Completed

A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD

Pulmonary Disease, Chronic Obstructive

United States, Germany, Philippines, Thailand, Korea, Republic of, Norway
GlaxoSmithKline

Completed

A 24-week Study of Fluticasone Furoate/Vilanterol Inhalation Powder in Subjects of Asian Ancestry With COPD

Pulmonary Disease, Chronic Obstructive

Taiwan, China, Philippines, Korea, Republic of
Organon and Co

Completed

Study of Mometasone Furoate/Formoterol Combination and Fluticasone/Salmeterol in Persistent Asthmatics Previously Treated With Inhaled Glucocorticosteroids (P04139)

Asthma
GlaxoSmithKline

Completed

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Fluticasone Furoate Nasal Spray for 2 Weeks in Chinese Adult and Adolescent Subjects With Allergic Rhinitis

Allergic Rhinitis | Rhinitis, Allergic, Perennial

China
GlaxoSmithKline

Completed

A Clinical Study To Test A Nasal Spray (Fluticasone Furoate Nasal Spray) For The Treatment Of Perennial (Year-round) Allergic Rhinitis

Rhinitis, Allergic, Perennial

Estonia, United States, Canada, Germany, Slovakia, Russian Federation, Hungary
GlaxoSmithKline

Completed

RELOVAIR® Lung Deflation Study

Pulmonary Disease, Chronic Obstructive

United Kingdom
Hvidovre University Hospital

Recruiting

Periostin-guided Withdrawal of Inhaled Corticosteroids in Patients With Non-eosinophilic Asthma

Asthma

Denmark
GlaxoSmithKline

Completed

Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily in Subjects With COPD Who Have or Are At Risk for Co-morbid Cardiovascular Disease

Pulmonary Disease, Chronic Obstructive

United States, Canada, Germany, Romania, Poland, Czechia
University of Saskatchewan

Completed

Effect of Fluticasone Furoate on Methacholine Challenge

Asthma

Canada
GlaxoSmithKline

Completed

Phase 4 Fluticasone Furoate Nasal Spray (VERAMYST) Long Term Pediatric Growth Study.

Rhinitis, Allergic, Perennial

United States, Argentina, Canada, France, Peru, Italy, Chile
GlaxoSmithKline

Completed

Pharmacokinetics and PharmacoDynamics of GW685698 in Paedeatric Asthmatic Patients

Asthma

United States
GlaxoSmithKline

Completed

Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Trifenatate in the Treatment of Asthma in Adolescent and Adult Subjects of Asian Ancestry.

Asthma

Korea, Republic of, China, Philippines
GlaxoSmithKline

Completed

Crossover Study Comparing Fluticasone Furoate (FF)/Vilanterol (VI) Once Daily Versus Fluticasone Propionate (FP) Twice Daily in Subjects With Asthma and Exercise-Induced Bronchoconstriction (EIB)

Asthma

United States, Canada
Johannes Gutenberg University Mainz

Completed

Disulfiram as a Modulator of Amyloid Precursor Protein-processing (DIMAP)

Alcohol Addiction
GlaxoSmithKline

Completed

Dose Ranging Study Evaluating the Efficacy and Safety of GSK2190915 Administered Once Daily

Asthma

United States, Japan, Romania, Ukraine, Bulgaria, Poland
GlaxoSmithKline

Completed

A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic (PD) Profiles of 3 Doses of Fluticasone Furoate (FF)/GW642444 Inhalation Powder at the End of a 28-day Treatment Period in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Compared to Placebo

Pulmonary Disease, Chronic Obstructive

United States
GlaxoSmithKline

Completed

A Clinical Study With Fluticasone Furoate Nasal Spray And Vehicle Placebo For The Treatment Of Perennial (Year-round) Allergic Rhinitis

Rhinitis, Allergic, Perennial

United States
Rush University Medical Center
GlaxoSmithKline

Completed

Study of the Effect of Fluticasone Furoate Nasal Spray on Spring Allergy Eye Symptoms

Allergic Conjunctivitis to Tree Pollen or Grass Pollen

United States
GlaxoSmithKline

Completed

A Pilot Study In Adults And Adolescents With Irritant (Non-Allergic) Rhinitis

Rhinitis, Allergic, Perennial

Thailand
GlaxoSmithKline

Completed

Regulatory AVAMYS Nasal Spray PMS

Rhinitis, Allergic, Perennial and Seasonal

Korea, Republic of
Novartis
Merck Sharp & Dohme LLC

Completed

Bronchodilatory Efficacy of a Single Dose QMF149 (Indacaterol Maleate/Mometasone Furoate) Via the Twisthaler® Device in Adult Patients With Asthma

Asthma

France, Germany
University of Chicago
GlaxoSmithKline

Completed

Intranasal Steroids and Oxymetazoline in Allergic Rhinitis

Allergic Rhinitis

United States
GlaxoSmithKline

Completed

A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Puerto Rico, United States, Australia, Argentina, France, Germany, Japan, Netherlands, Russian Federation, Spain, Ukraine, Finland, Czechia, Poland, Belgium, Chile, Peru, South Africa, Sweden, Thailand, Israel, Korea, Republic of, C... and more
GlaxoSmithKline

Completed

Randomised Study Comparing the Effects of Inhaled FF/GW642444M Combination, FF and GW642444M on an Allergen Induced Asthmatic Response

Asthma

Sweden, Australia, New Zealand
GlaxoSmithKline

Completed

Relovair PD PK in Chinese Healthy Subjects

Asthma

China
GlaxoSmithKline

Completed

Randomised Study Comparing the Effects of Inhaled Fluticasone Furoate (FF)/Vilanterol (VI; GW642444M) Combination and FF on an Allergen Induced Asthmatic Response

Asthma

United Kingdom, Germany, New Zealand
Gilead Sciences

Completed

COMBISTRAT: AmBisome® in Combination With Caspofungin for the Treatment of Invasive Aspergillosis

Invasive Aspergillosis

France
Bispebjerg Hospital
Rigshospitalet, Denmark

Completed

Urine Concentrations of Vilanterol After Inhaled Administration of Vilanterol/Fluticasone Furoate

Pharmacokinetics

Denmark
GlaxoSmithKline

Completed

Dose-ranging Study of Vilanterol (VI) Inhalation Powder in Children

Asthma

United States, Argentina, Germany, Japan, Chile, Peru, Philippines, Poland, Mexico, Slovakia, Ukraine, South Africa, Puerto Rico, Georgia
Novartis

Completed

Investigation of the 24 Hour Forced Expiratory Flow in 1 Second (FEV1) Profile of a Single Dose of Indacaterol/Mometasone Delivered Via the TWISTHALER® Device in Adult Patients With Persistent Asthma

Asthma

Germany, Belgium
GlaxoSmithKline

Withdrawn

Shortness Of Breath Questionnaire Validation Study

Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline

Withdrawn

A Study Comparing the Closed Triple Therapy, Open Triple Therapy and a Dual Therapy for Effect on Lung Function in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Canada, Germany
GlaxoSmithKline

Completed

A Phase IIA FF/VI Study to Measure FeNO in Asthmatic Patients.

Asthma

New Zealand
Murdoch Childrens Research Institute
Royal Children's Hospital; Monash Health

Recruiting

Intranasal Steroid as Medical Therapy For Sleep-Disordered Breathing in Children (MIST+)

Snoring | Tonsillar Hypertrophy | Sleep Disorder; Breathing-Related | Obstructive Sleep Apnea of Child | Sleep Disorders in Children | Adenoidal Disorder

Australia
Federico II University

Unknown

Effects of the Direct Interaction Between Streptococcus Salivarius 24SMBc and Streptococcus Oralis 89a and the Respiratory Epithelium in Children

Allergy

3

Subscribe